A fungus in Utah soil can lead to lung infections — but officials say there is ‘no reason to panic'
'Washington County has the highest rate of Valley fever in the state,' Dr. Katharine S. Walter told ABC4.com. 'And we think it is severely underreported compared to parts of California and Arizona, which are very well known to be endemic for the fungus.'
, or Coccidioidomycosis, is a fungal lung infection that like fatigue, cough, fever, shortness of breath, and a rash. It occurs after spores from Coccidioides — which live in soil and dust in — are breathed in.
If the FDA removes fluoride supplements, are there other options to protect teeth? Dentist weighs in
Dr. Walter and Dr. Ginamarie Foglia — both epidemiologists — presented during a lecture series in southern Utah about the effects of Valley fever and concerns related to the changing environment. The aim of the event was to spread awareness of the prevalence of Valley fever, not to spread fear.
'There's no reason to panic,' Foglia told ABC4.com. 'It's manageable. It's just that many people don't know what it is.'
Foglia said that while Utahns should not panic about the potential for these types of infections, it is important to know what the risks and symptoms are. An understanding of the symptoms could help people better manage the infection.
'Many times it's seen as a bacterial infection, and people are given antibiotics, they don't get better,' Foglia said. 'So, it's really to alert people and to make them aware that it exists here.'
The says many people who have Valley fever experience mild symptoms, and 'often get better without medication within a few months.' In some cases, severe infections may spread to other parts of the body, and cause patients to need more long-term treatment.
'This is a disease we should all be worried about because everyone is at risk, and the people at most risk are the people who work outside, who are constantly exposed to dust and soil, like agricultural workers — construction workers,' Walter said.
Valley fever occurs after spores from Coccidioides — which live in soil and dust in — are breathed in. When that soil or dust is disturbed (such as during construction or a windstorm), the risk of breathing in those spores increases.
The CDC reports that many people do not get sick from breathing in the spores, and most people who do fall ill get better on their own. However, for developing severe forms of Valley fever.
If symptoms of Valley fever last longer than a week, officials recommend visiting a healthcare provider.
Valley fever is , according to the CDC. Between 10,000 and 20,000 cases are reported to the CDC each year, with most cases reported in Arizona and California.
'Cases frequently are never diagnosed or misdiagnosed because many patients are not tested for Valley fever,' the CDC says.
Foglia and Walter said many people often receive a delayed Valley fever diagnosis after initially being diagnosed with a bacterial infection. Walter also spoke about the potential role played by climate change in expanding the areas where the fungus can be found.
'We think that with a changing climate, that the area where the fungus can thrive and survive is likely to expand and change, and that's one thing we really need to study,' Walter said.
The CDC says it is 'very difficult to avoid breathing in the fungus' — but there are still ways to help reduce exposure.
For example, the CDC recommends using air filtration methods when indoors and avoiding areas (like construction sites) that have a lot of dust. Wearing an N95 respirator when around dust may also help, the CDC says.
For more detailed explanations about Valley fever and prevention methods, .
Joseph Degolyer contributed to this report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
an hour ago
- Business Wire
European Commission Approves CAR-T Therapy With
MILAN--(BUSINESS WIRE)--Following news on July 21 that the European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel – obe-cel), AGC Biologics' Milan site achieved its 10th product approval from the European Medicines Agency or the U.S. Food and Drug Administration. Developed by Autolus Therapeutics, AUCATZYL® is now approved to treat adult patients (age 26 and older) in 27 European Union member states with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This follows the therapy's prior authorizations from the FDA in November 2024 and the U.K. Medicines and Healthcare products Regulatory Agency in April 2025. This latest step further solidifies AGC Biologics' Milan Cell and Gene Center of Excellence's reputation as a global leader in the field, built on a 30-year track record of quality, reliability, and regulatory success. 'This European approval for Autolus is a milestone we are thrilled to be part of. Our goal is to be the industry's safe harbor: a trusted, friendly expert CDMO that de-risks the complex path to commercialization,' said Alberto Santagostino, CEO and President, AGC Biologics. 'By ensuring a reliable supply of their vital lentiviral vector, we empower our partners to focus on patients. Congratulations to the entire Autolus team.' The partnership between Autolus and AGC Biologics Milan began in 2020, with the CDMO tasked to develop, manufacture, and supply the viral vectors for Autolus' obe-cel CAR-T product candidate. 'From the start of our partnership in 2020, through the FDA approval and now this European authorization, our collaboration with Autolus has been a model of true partnership,' said Luca Alberici, General Manager, AGC Biologics Milan. 'The team's sustained dedication and technical excellence is a direct result of our ability to work seamlessly with the Autolus team to meet the demands of commercial-scale manufacturing for a global market.' With its 30-year track record and 10 product approvals by the EMA and FDA, the AGC Biologics Milan site is a global leader with deep expertise in complex cell and gene therapy projects. The team has guided numerous products to commercial stages, manufactured hundreds of batches for clinical supply, and consistently met the highest global regulatory guidelines, quality performance metrics, and the unique complexities of technology transfers and manufacturing scale-up. To learn more about AGC Biologics' global cell therapy services, visit and for more on the CDMO's viral vector offerings, visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit AUCATZYL® (obecabtagene autoleucel – obe-cel) is a registered trademark of Autolus Therapeutics.


New York Times
an hour ago
- New York Times
New Implant Offers Hope for Easing Rheumatoid Arthritis
The Food and Drug Administration on Wednesday approved a medical device that offers new hope to patients incapacitated by rheumatoid arthritis, a chronic condition that afflicts 1.5 million Americans and is often resistant to treatment. The condition is usually managed with medications. The device represents a radical departure from standard care, tapping the power of the brain and nervous system to tamp down the uncontrolled inflammation that leads to the debilitating autoimmune disease. The SetPoint System is an inch-long device that is surgically implanted into the neck, where it sits in a pod wrapped around the vagus nerve, the largest nerve in the body. The device electrically stimulates the nerve, a sort of information freeway through the body, for one minute each day. The stimulation can turn off crippling inflammation and 'reset' the immune system, research has shown. Most drugs used to treat rheumatoid arthritis suppress the immune system, leaving patients vulnerable to serious infections. On a recent episode of the American College of Rheumatology podcast, the SetPoint implant was described as representing a 'true paradigm shift' in treatment of the disease, which until now has relied almost entirely on an evolving set of pharmaceutical interventions, from gold salts to powerful agents called biologics. The designated the implant as a breakthrough last year in order to expedite its development and approval. It represents an early test of the promise of so-called bioelectronic medicine to modulate inflammation, which plays a key role in diseases including diabetes, heart disease and cancer. Want all of The Times? Subscribe.


Politico
2 hours ago
- Politico
Why Trump ordered ouster of FDA official
With help from Amanda Friedman Driving the Day THE PRASAD BACKSTORY — President Donald Trump drove the push to oust the FDA's top vaccine regulator, four people with knowledge of the decision told POLITICO's David Lim and Lauren Gardner, despite the protests of Health Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary. The former official, Vinay Prasad, had been on the job three months and had recently come under attack by conservative provocateur Laura Loomer. 'I worry now RFK will get hardcore anti-vaxxers in there,' said one of the four, who were granted anonymity to discuss Trump's decision. Loomer's attack: A close Trump ally, Loomer's efforts against Prasad began in earnest on July 20 when she wrote on her website that Prasad, a hematologist-oncologist, was a 'progressive leftist saboteur undermining President Trump's FDA.' She called attention to his 2021 social media posts in which he called himself 'a political liberal' aligned with Sens. Bernie Sanders (I-Vt.) and Elizabeth Warren (D-Mass.). Loomer also linked to his 2020 post on the social media platform X, where he expressed support for then-candidate Joe Biden to win the presidential election that November. 'Prasad's policy positions are a direct affront to the conservative principles underpinning Trump's agenda,' Loomer wrote, listing his support for universal health care and abortion rights. Loomer could not be reached for comment on Prasad's departure. Elevidys dispute: Loomer and other conservative voices also slammed Prasad's stewardship of rare disease therapies under his center's purview, arguing his approach threatened patient choice. Those complaints came amid a skirmish between the FDA and Sarepta Therapeutics over whether the drugmaker should pause shipments of Elevidys, a treatment for Duchenne muscular dystrophy, a severe genetic disorder that overwhelmingly impacts young males. Prasad vocally critiqued the decision by his predecessor, Dr. Peter Marks, to approve the drug for nearly all patients in June 2024. The FDA asked Sarepta to suspend all shipments of the therapy, but the company initially refused to do so for ambulatory patients. It subsequently agreed to the pause, but on Monday, the FDA allowed them to resume distribution to patients who can still walk. Sen. Ron Johnson (R-Wis.) said he conveyed concern about the FDA's approach to Elevidys to Kennedy, who set up a call with Makary. But Johnson subsequently raised the issue with the White House on Monday morning. 'I just texted President Trump on Monday just to make sure he was aware of the situation,' Johnson said Wednesday. What's next: Makary on Wednesday announced that Dr. George Tidmarsh would take over as acting director of the Center for Biologics Evaluation and Research — but more substantial changes could be on the horizon. The Trump administration is weighing whether to split CBER into two bodies: one focused on vaccine regulation and one on therapeutics, according to three of the people familiar with the discussions. That could allow Kennedy to respond to anti-vaccine groups like Children's Health Defense, which has expressed concern he hasn't been as aggressive toward immunizations as they had hoped. Under Prasad, the FDA approved Moderna's Covid-19 vaccine for kids ages 6 months through 11 years at increased risk for Covid. Prasad was also instrumental in developing the FDA's framework for approval of future Covid booster shots. WELCOME TO THURSDAY PULSE. Beverage brand High Noon is recalling some of its Beach Variety 12-packs, saying some packages may contain Celsius energy drink cans filled with vodka seltzers. Confusing! Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. MORNING MONEY: CAPITAL RISK — POLITICO's flagship financial newsletter has a new Friday edition built for the economic era we're living in: one shaped by political volatility, disruption and a wave of policy decisions with sector-wide consequences. Each week, Morning Money: Capital Risk brings sharp reporting and analysis on how political risk is moving markets and how investors are adapting. Want to know how health care regulation, tariffs or court rulings could ripple through the economy? Start here. In Congress HHS SPENDING FIGHT COMMENCES — The Senate Appropriations Committee is slated to mark up the Labor-HHS-Education spending package today — offering a first glimpse into how agreeable the upper chamber will be to President Donald Trump's proposed HHS overhaul. The committee will first vote to approve the bill at the beginning of the markup and then debate and vote on amendments. The Labor-HHS-Education bill has always been considered one of the more contentious bills, and the Trump administration's proposal to slash HHS funding is expected to further complicate the process. What Trump wants: Trump's proposed budget would cut HHS by around $31.3 billion in fiscal 2026, with the NIH and the CDC seeing the steepest funding cuts. The proposal would also largely reform the agency to reflect Trump's and HHS Secretary Robert F. Kennedy Jr.'s desire to implement the Make America Healthy Again agenda, which includes creating a new agency called the Administration for a Healthy America to focus on chronic disease, funded at $20.6 billion. Where the House stands: The House punted its Labor-HHS-Education markup until after August recess when the chamber decided to head out early. 'We're right now scheduled to do it the first week after we get back from Labor Day,' Rep. Robert Aderholt, who chairs the Labor-HHS-Education Subcommittee on the House Appropriations panel, told POLITICO's Mackenzie Wilkes earlier this month. Collectively, the House lawmakers propose funding the departments of Education, Labor and HHS and related agencies at more than $184 billion, according to updated subcommittee allocations released by the committee, but the breakdown for each agency is still unclear. HHS NOMINEES PROGRESS — The Senate Finance Committee is scheduled to consider President Donald Trump's nomination of Gustav Chiarello for HHS assistant secretary today, Amanda reports. The leading antitrust lawyer would serve as the senior public health adviser to HHS Secretary Robert F. Kennedy Jr. if confirmed. Background: Chiarello was most recently the senior special counsel at the House Judiciary Committee and, previously, an attorney with the Federal Trade Commission, working on hospital merger investigations. Alongside Chiarello, senators will consider West Virginia GOP state Sen. Michael Stuart's nomination for HHS general counsel. THE VIEW FROM MAIN ST. — Rep. Mike Flood (R-Neb.) is the new chair of the Main Street Caucus, made up of more than 80 self-described 'pragmatic conservatives who get things done.' Flood plans to use his caucus to create 'severe pushback' if Republicans try to slash Medicaid in a second budget reconciliation bill, he told POLITICO's Meredith Lee Hill. 'Main Street lobbied very heavily for the $50 billion rural health care fund. Main Street supported the work requirements and not giving Medicaid to illegal immigrants. We supported SNAP changes. But I would imagine that there would be a lot of resistance from a good swath of the Main Street Caucus on any further cuts to Medicaid,' Flood said. ACA tax credit extension? Flood was more coy about where the caucus stands on extending the Affordable Care Act's enhanced tax credits, which are set to expire at the end of 2025. 'I have the same answer on this that Speaker [Mike] Johnson has, and that is, we haven't even got to that yet,' he said. 'We had [CMS Administrator] Dr. [Mehmet] Oz in to see us. He's engaging with a lot of our members over the August recess. I imagine we'll reset the table here after government funding and then start talking about that.' At the White House EASING DATA ACCESS — The Trump administration launched a new patient data modernization push Wednesday, convening CEOs from 60 companies who agreed to make it easier for patients to access their medical information, POLITICO's Ruth Reader reports. 'America's health care networks have been overdue for a high-tech upgrade, and that's what we're doing,' President Donald Trump said. Who's involved? Major tech companies, including Amazon, Anthropic, Apple, Google and OpenAI and identity verification company Clear, were among the businesses that said they would help make patient records more accessible. Health providers that signed include the Cleveland Clinic, Sanford Health and Intermountain Health Care. Data networks signing on include medical records giant Epic and Oracle Health. What are they doing? As POLITICO reported last week, the agreement would encourage companies to free up data so patients could input their medical records into apps and artificial intelligence programs that can help inform choices they make about their diet, fitness and health. It would also allow doctors and others involved in patient care to more easily access the records. 'The key here is the unlocking of the data, because the more data that AI has, the better it performs,' said David Sacks, the White House artificial intelligence and crypto czar, at a White House event. The administration also asked app developers to create programs for Medicare and Medicaid patients. Weight-loss app Noom said it would offer 30-day free trials of its healthy-weight program and Diabetes Prevention Program for Medicare recipients and announced a free version of its app. CMS has signaled it would make partner apps available in an app store on Amy Gleason, acting administrator of the Department of Government Efficiency, who led this initiative, also promised to modernize and enhance its interoperability. But, but, but: The federal government has tried similar tactics in the past, including during the Obama administration, with limited success. WHAT WE'RE READING STAT's Katherine Eban reports that the person intended to serve as the head of the White House Office of Pandemic Preparedness and Response Policy, Gerald Parker, has resigned. KFF Health News' Jazmin Orozco Rodriguez reports on how tribal groups aim to push back against the Trump administration's crackdown on gender-affirming care.